Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €9.61 EUR
Change Today -0.233 / -2.37%
Volume 0.0
VM4 On Other Exchanges
As of 11:25 AM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VM4) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/15 - €12.56
52 Week Low
10/13/14 - €6.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

vanda pharmaceuticals inc (VM4) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VM4) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products include HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also include Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

105 Employees
Last Reported Date: 07/31/15
Founded in 2002

vanda pharmaceuticals inc (VM4) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $580.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

vanda pharmaceuticals inc (VM4) Key Developments

FDA Accepts for Review Vanda's Filing of a Supplemental New Drug Application for Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults

Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review Vanda's filing of a supplemental New Drug Application (sNDA) for Fanapt® seeking approval as a maintenance treatment of schizophrenia in adults. Vanda is seeking approval based on the results of the REPRIEVE clinical study, which evaluated the long-term maintenance of efficacy and safety of Fanapt®. The FDA has set a user fee goal date under the Prescription Drug User Fee Act of May 27, 2016, which is the target date for the FDA to complete its review of the sNDA.

Vanda Pharmaceuticals, Inc. Appoints Richard Gulino as Senior Vice President, General Counsel and Secretary

Vanda Pharmaceuticals Inc. announced that it has named Richard Gulino as Vanda's Senior Vice President, General Counsel and Secretary. Mr. Gulino has over 20 years of strategic and legal experience representing life sciences and healthcare companies. Prior to joining Vanda, Mr. Gulino served as Vice President and General Counsel of Ameritox Ltd. Prior to this position, Mr. Gulino was Vice President and Deputy General Counsel at Cephalon, Inc. Before joining Cephalon, Mr. Gulino served as a senior commercial attorney at Zeneca, Inc.

Vanda Pharmaceuticals Inc. Names Gian Piero Reverberi as Senior Vice President and European General Manager

Vanda Pharmaceuticals Inc. announced that it has named Gian Piero Reverberi as Vanda's Senior Vice President, European General Manager. Mr. Reverberi has more than 20 years of experience in the pharmaceutical industry, holding senior management and regional leadership positions over the last 10 years. Prior to joining Vanda, Mr. Reverberi acted as a corporate advisor supporting several companies in the development of their commercial and geographical expansion strategies. Mr. Reverberi served as Senior Vice President, International Specialty Pharma at Shire Pharmaceuticals, with responsibility for Shire's specialty pharma business in EMEA, Canada, Australia, Japan, Asia Pacific and Latin America.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VM4:GR €9.61 EUR -0.233

VM4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,161 GBp +48.50
Bristol-Myers Squibb Co $60.51 USD -0.04
Eli Lilly & Co $83.77 USD -0.22
Pernix Therapeutics Holdings Inc $3.11 USD -0.11
Sanofi €86.10 EUR +0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation VM4 Industry Range
Price/Earnings 9.4x
Price/Sales 6.4x
Price/Book 3.4x
Price/Cash Flow 8.4x
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at